Your browser doesn't support javascript.
loading
Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma.
Wu, Lingxiang; Wu, Wei; Zhang, Junxia; Zhao, Zheng; Li, Liangyu; Zhu, Mengyan; Wu, Min; Wu, Fan; Zhou, Fengqi; Du, Yuxin; Chai, Rui-Chao; Zhang, Wei; Qiu, Xiaoguang; Liu, Quanzhong; Wang, Ziyu; Li, Jie; Li, Kening; Chen, Apeng; Jiang, Yinan; Xiao, Xiangwei; Zou, Han; Srivastava, Rashmi; Zhang, Tingting; Cai, Yun; Liang, Yuan; Huang, Bin; Zhang, Ruohan; Lin, Fan; Hu, Lang; Wang, Xiuxing; Qian, Xu; Lv, Sali; Hu, Baoli; Zheng, Siyuan; Hu, Zhibin; Shen, Hongbing; You, Yongping; Verhaak, Roel G W; Jiang, Tao; Wang, Qianghu.
Afiliación
  • Wu L; The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
  • Wu W; Department of Bioinformatics, Nanjing Medical University, Nanjing, China.
  • Zhang J; Institute for Brain Tumors, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
  • Zhao Z; The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
  • Li L; Department of Bioinformatics, Nanjing Medical University, Nanjing, China.
  • Zhu M; Institute for Brain Tumors, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
  • Wu M; Institute for Brain Tumors, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
  • Wu F; Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Zhou F; Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
  • Du Y; Department of Bioinformatics, Nanjing Medical University, Nanjing, China.
  • Chai RC; Institute for Brain Tumors, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
  • Zhang W; The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
  • Qiu X; Department of Bioinformatics, Nanjing Medical University, Nanjing, China.
  • Liu Q; Institute for Brain Tumors, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
  • Wang Z; The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
  • Li J; Department of Bioinformatics, Nanjing Medical University, Nanjing, China.
  • Li K; Institute for Brain Tumors, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
  • Chen A; Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
  • Jiang Y; Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Xiao X; The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
  • Zou H; Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
  • Srivastava R; Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Zhang T; Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Cai Y; The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
  • Liang Y; Department of Bioinformatics, Nanjing Medical University, Nanjing, China.
  • Huang B; Institute for Brain Tumors, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
  • Zhang R; Department of Bioinformatics, Nanjing Medical University, Nanjing, China.
  • Lin F; Institute for Brain Tumors, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
  • Hu L; Department of Bioinformatics, Nanjing Medical University, Nanjing, China.
  • Wang X; Institute for Brain Tumors, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
  • Qian X; The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
  • Lv S; Department of Bioinformatics, Nanjing Medical University, Nanjing, China.
  • Hu B; Institute for Brain Tumors, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
  • Zheng S; State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China.
  • Hu Z; Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • Shen H; John G. Rangos Sr. Research Center, University of Pittsburgh Medical Center (UPMC) Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.
  • You Y; John G. Rangos Sr. Research Center, University of Pittsburgh Medical Center (UPMC) Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.
  • Verhaak RGW; Department of Pediatric Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • Jiang T; John G. Rangos Sr. Research Center, University of Pittsburgh Medical Center (UPMC) Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.
  • Wang Q; Department of Pediatric Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Cancer Discov ; 12(12): 2820-2837, 2022 12 02.
Article en En | MEDLINE | ID: mdl-36122307
Isocitrate dehydrogenase (IDH) wild-type glioblastoma (GBM) has a dismal prognosis. A better understanding of tumor evolution holds the key to developing more effective treatment. Here we study GBM's natural evolutionary trajectory by using rare multifocal samples. We sequenced 61,062 single cells from eight multifocal IDH wild-type primary GBMs and defined a natural evolution signature (NES) of the tumor. We show that the NES significantly associates with the activation of transcription factors that regulate brain development, including MYBL2 and FOSL2. Hypoxia is involved in inducing NES transition potentially via activation of the HIF1A-FOSL2 axis. High-NES tumor cells could recruit and polarize bone marrow-derived macrophages through activation of the FOSL2-ANXA1-FPR1/3 axis. These polarized macrophages can efficiently suppress T-cell activity and accelerate NES transition in tumor cells. Moreover, the polarized macrophages could upregulate CCL2 to induce tumor cell migration. SIGNIFICANCE: GBM progression could be induced by hypoxia via the HIF1A-FOSL2 axis. Tumor-derived ANXA1 is associated with recruitment and polarization of bone marrow-derived macrophages to suppress the immunoenvironment. The polarized macrophages promote tumor cell NES transition and migration. This article is highlighted in the In This Issue feature, p. 2711.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Glioblastoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Discov Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Glioblastoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Discov Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos